Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases

An inflammatory disease, immune-mediated technology, applied in the direction of resistance to vector-borne diseases, drug combinations, allergic diseases, etc., can solve problems such as destroying tumors, reducing cancer immunity, anti-tumor effects, and cancer progression damage

Pending Publication Date: 2022-01-21
ALVIT LCS PHARMA LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Reduction of immune-mediated processes may have positive effects in some clinical indications, but may negatively affect processes requiring immunostimulatory and anti-inflammatory effects such as cancer
[0004] In addition, most chemotherapeutic agents used to treat cancer may destroy tumors and prevent cancer progression as well as damage healthy cells and tissues during the course of treatment. In addition, negative effects on cancer immunity may reduce some of their beneficial anti-tumor effects
[0005] Therefore, there is an unmet need for new more effective and safer agents for use as anticancer therapy and treatment of other immune-mediated inflammatory diseases (IMIDs)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases
  • Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases
  • Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0243] To assess the anti-inflammatory properties of the composition of the invention, assays of nitric oxide (NO) and cytokine secretion from RAW cells following incubation with mushroom extracts and cannabinoids, as well as viability assays were performed.

[0244] Table 1: *Suggested Assay Design

[0245]

[0246]

[0247] *Rows marked in red are plate set up

[0248] **Only in CBD / THC board

[0249] Table 2: Plate setup for mushroom extracts (4 mushrooms / plate)

[0250]

[0251]

[0252] Table 3: Plate setup for cannabinoid extracts

[0253]

[0254] Cell proliferation and viability (XTT assay)

[0255] a. Preparation of XTT reaction solution.

[0256] b. Add 50 μL of XTT reaction solution to each well.

[0257] c. Place the plate in a humid atmosphere (e.g. 37°C, 5% CO 2 ) incubate.

[0258] d. Shake the plate gently to distribute the dye evenly in the wells.

[0259] e. Measure the absorbance of the samples with a spectrophotometer (ELISA reader) a...

example 2

[0359] Viability assay of panc-1 and gl-1 cells after treatment with various combinations of mushroom extracts and cannabinoids

[0360] test system

[0361] a. PANC-1 cells (human pancreatic cancer cells) (American Type Culture Collection, Rockville, MD, USA).

[0362] b. EGL-1 cells (human extrahepatic cholangiocarcinoma)

[0363] Cell growth:

[0364] Growth medium suitable for PANC-1 / EGL-1 cells: Dulbecco's (S. ) Modified Eagle's medium (DMEM) high glucose.

[0365] Suitable growth medium for EGL-1 cells: RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and 1% penicillin-streptomycin solution (PS).

[0366] Assay medium suitable for PANC-1: Assay medium contains only 1% FBS.

[0367] Assay medium suitable for EGL-1: Assay medium contains only 1% FBS in DMEM low glucose (1 g / L)

[0368] Experimental Design: Incubate cells with test item:

[0369] a. Cells were harvested at 80% confluency, counted and resuspended in growth medium to a ...

example 3

[0393] Cancer Study Results: Mushroom Extracts

[0394]

[0395] a. Seven mushroom extracts were incubated with 0.5-10 mg / ml of PANC-1 or EGL-1 for 72 hours.

[0396] b. Tables 12 and 13 describe the doses of mushrooms that resulted in the greatest kill (lowest viability).

[0397] c. Test the viability of the cells (XTT assay).

[0398] d. EGL-1 cells are much more resistant to cell death than PANC-1 cells. Cordyceps M (RM) was the most effective mushroom, followed by Ganoderma lucidum.

[0399] e. PANC-1 cells: Chaga was the most effective mushroom, followed by Ganoderma lucidum and Turkey Tail (MS).

[0400] f. The results are shown in Figures 7 and 8.

[0401] Table 12: Summary of PANC-1 Cell Viability*

[0402]

[0403]

[0404]

[0405] Table 13: Summary of viability in EGL-1 cells

[0406]

[0407]

[0408]

[0409] The results showed that both EGL-1 and PANC-1 cells incubated with Agaricus and Cordyseps Cs-4(MS) exhibited a % viability higher...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects is disclosed. The composition comprises a synergistic combination of a cannabis derived compound, and a medicinal mushroom.

Description

technical field [0001] The present invention generally relates to means and methods for novel treatment of cancer, inflammatory or immune-mediated inflammatory diseases. [0002] More specifically, the present invention relates to synergistic interactions and fixed dose combinations of cannabinoids and medicinal mushrooms for the prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases. Background technique [0003] While cannabinoids (CBD, THC, and some others) are known to be potent anti-inflammatory agents with known anticancer activity, it has also been found that these compounds may impair, inhibit, or attenuate immune-mediated processes. Reduction of immune-mediated processes may have positive effects in some clinical indications, but may negatively affect processes requiring immunostimulatory and anti-inflammatory effects such as cancer. [0004] In addition, most chemotherapeutic agents used to treat cancer may destroy tumors and pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K36/06A61K36/068A61K31/05A61K36/00A61P35/00A61P37/00
CPCA61K36/068A61P37/00A61P35/00A61K31/352A61K31/05A61K45/06A61K36/185A61K36/074A61K36/07A61K2300/00A61P37/06A61K36/062
Inventor I·拉门斯多夫Y·雷维
Owner ALVIT LCS PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap